Zivo Bioscience (ZIVO) director Alison Cornell buys 11,709 shares at $8.54

Rhea-AI Filing Summary

Zivo Bioscience director Alison Cornell reported buying additional company stock. On January 26, 2026, she purchased 11,709 shares of common stock at a price of $8.54 per share. Following this transaction, she directly beneficially owns 279,481 shares of Zivo Bioscience common stock.

Insider Trade Summary

Net Buyer: 11,709 shares ($99,995)

Net Buy 1 txn

Insider Cornell Alison A

Role Director

Bought 11,709 shs ($100K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	11,709	$8.54	$100K

Holdings After Transaction: Common Stock — 279,481 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cornell Alison A

(Last) (First) (Middle)

2125 BUTTERFIELD DRIVE

SUITE 100

(Street)

TROY MI 48084

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zivo Bioscience, Inc. [ ZIVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		P		11,709	A	$8.54	279,481	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Alison Cornell	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Zivo Bioscience (ZIVO) report for Alison Cornell?

Zivo Bioscience reported that director Alison Cornell purchased 11,709 shares of common stock. The shares were acquired in an open market transaction at a price of $8.54 per share, increasing her directly held stake in the company.

How many Zivo Bioscience (ZIVO) shares does Alison Cornell own after this Form 4?

After the reported transaction, Alison Cornell beneficially owns 279,481 shares of Zivo Bioscience common stock. This figure reflects her direct ownership position immediately following the January 26, 2026 open market share purchase.

What was the price paid per share in the latest Zivo Bioscience (ZIVO) insider purchase?

In the reported transaction, Zivo Bioscience director Alison Cornell paid $8.54 per share. This price applied to all 11,709 common shares she acquired on January 26, 2026, as disclosed in the Form 4 filing.

What is the role of Alison Cornell at Zivo Bioscience (ZIVO) according to the filing?

The filing identifies Alison Cornell as a director of Zivo Bioscience. She is not listed as an officer or 10% owner in this Form 4, and the form indicates it is filed for one reporting person only.

Was the Zivo Bioscience (ZIVO) insider transaction a purchase or a sale?

The transaction was a purchase of common stock, coded "P" on the Form 4. Director Alison Cornell acquired 11,709 shares on January 26, 2026, increasing her direct beneficial ownership to a total of 279,481 shares.